ABSTRACT
Introduction Limitations in effective dementia therapies mean that early diagnosis and monitoring are critical for disease management, but current clinical tools are impractical and/or unreliable, and disregard short-term symptom variability. Behavioural biomarkers of cognitive decline, such as speech, sleep and activity patterns, can manifest prodromal pathological changes. They can be continuously measured at home with smart sensing technologies, and permit leveraging of interpersonal interactions for optimising diagnostic and prognostic performance. Here we describe the ContinUous behavioural Biomarkers Of cognitive Impairment (CUBOId) study, which explores the feasibility of multimodal data fusion for in-home monitoring of mild cognitive impairment (MCI) and early Alzheimer’s disease (AD). The report focuses on a subset of CUBOId participants who perform a novel speech task, the “TV task”, designed to track changes in ecologically valid conversations with disease progression.
Methods and Analysis Participants have diagnoses of MCI or AD, and controls are their live-in partners with no such diagnosis. Multimodal activity data were passively acquired from wearables and in-home fixed sensors over periods ranging from 8 to 25 months. At 2 time points participants completed the TV task over 5 days by recording audio of their conversations as they watched a favourite TV programme, with further testing to be completed after removal of the sensor installations. Behavioural testing is supported by neuropsychological assessment for deriving behavioural ground truths on cognitive status. Deep learning will be used to generate fused multimodal activity-speech embeddings for optimisation of diagnostic and predictive performance from speech alone.
Ethics and dissemination CUBOId was approved by an NHS Research Ethics Committee (Wales REC; ref: 18/WA/0158) and is sponsored by University of Bristol. It is also supported by the National Institute for Health Research (NIHR) Clinical Research Network West of England. Results will be reported at conferences and in peer-reviewed scientific journals.
Strengths and limitations
To our knowledge, this is the first study to simultaneously characterise longitudinal, ecologically valid diagnostic trajectories across a broad range of behavioural domains relevant to cognitive decline “in the wild”, allowing construction of shared multimodal embeddings for dementia diagnosis from speech alone
Participants’ live-in partners are contextually matched controls, accounting for differences across participants’ home environments and lifestyles
Measurements of cognitive status from neuropsychological testing form ground truths for behavioural biomarkers of cognitive decline
Limited sample size and restricted demographics may confer limited generalisability of findings to other populations
Behavioural and neuropsychological testing timelines disrupted and desynchronised due to COVID-19
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by CUBOId (UK MRC Momentum grant MC/PC/16029), the SPHERE IRC (grant EP/K031910/1) and supported by the EPSRC Digital Health and Care Centre for Doctoral Training (CDT) at the University of Bristol (UKRI Grant No. EP/S023704/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Wales Research Ethics Committee 7 (ref: 18/WA/0158) and the Health Research Authority (IRAS project ID 234027) of the National Health Service gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All individuals in the CUBOId team have unrestricted access to the full dataset. Results will be reported at conferences, in peer-reviewed scientific journals and on the UoB website. Both the anonymised data and study documentation are stored on secure servers within UoB and shared according to UoB procedures and guidelines. Personally identifiable information is stored separately to research data. Data management procedures follow the stipulations of the General Data Protection Regulation. In line with NIHR guidance, we obtained consent for participant data to be stored for up to 20 years and shared anonymously with other researchers, after appropriate review to ensure it will be used according to the ethics approval.
